Crystagen

Crystagen (L-glutamyl-L-aspartyl-L-proline; EDP tripeptide; molecular formula C14H21N3O8; molecular weight 359.33 g/mol) is a synthetic tripeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as one of the principal short-peptide bioactive components of Thymalin, a bovine thymus polypeptide extract approved in the Soviet Union and Russian Federation since 1982 for clinical immunocorrection [1, 2]. The compound belongs to the Khavinson class of ultrashort (two to seven residue) peptide bioregulators, a family of synthetic sequences modeled on tissue-specific peptide fragments isolated from organ extracts by acid-pepsin hydrolysis and ultrafiltration, and is designated as the thymic immune system bioregulator within this peptide family. Crystagen shares the Glu-Asp dipeptide core with the bronchial bioregulator Chonluten (Glu-Asp-Gly) and the cortical bioregulator Cortagen (Ala-Glu-Asp-Pro), differing from these compounds by the third-position proline residue and the absence of the N-terminal alanine extension, respectively; the single amino acid substitution at the third position determines tissue specificity within the Khavinson classification [3, 4]. In the Khavinson laboratory internal code system, the compound is designated T-36 [5]. The principal molecular mechanism of Crystagen, characterized through molecular modeling, cell culture, and organotypic tissue studies, is epigenetic regulation of gene expression through direct interaction of the tripeptide with double-stranded DNA in gene promoter regions and with histone proteins (H1, H2B, H3, H4), producing chromatin decondensation and reactivation of age-repressed transcriptional programs in immune cells [6, 7, 8]. The immunomodulatory activity, characterized in thymic cell cultures, splenic organotypic cultures, and in the THP-1 monocyte/macrophage cell line, includes stimulation of T-lymphocyte differentiation with increased CD3+ and CD4+ cell populations, normalization of the CD4+/CD8+ ratio, activation of B-cell immunity in the spleen, suppression of thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, enhancement of normal lymphocyte proliferation with concurrent inhibition of K-562 tumor cell proliferation, and modulation of cytokine expression including interleukin-6 normalization [9, 10, 11, 12]. The cytoprotective profile includes a pronounced upregulation of heat-shock protein gene HSPA1A (encoding HSP-70), with expression increasing approximately 2.2-fold relative to baseline in a study of highly trained female artistic gymnasts receiving Crystagen in combination with other peptide bioregulators, an effect accompanied by reduced incidence of acute respiratory infections during epidemic conditions [13, 14]. In a clinical observational study of elderly patients, oral Crystagen administration normalized immunogram parameters in 82 percent of treated individuals compared to 56 percent in the control group [15]. The geroprotective context for Crystagen derives from the parent compound Thymalin, which in a 266-patient, 6-to-8-year prospective clinical study conducted at the Saint Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences produced a 2.0-to-2.1-fold reduction in mortality rate relative to control, and a 4.1-fold mortality reduction when combined with the pineal peptide Epithalamin [16]. No formal pharmacokinetic studies have been published for Crystagen as the isolated synthetic EDP tripeptide. As a linear tripeptide with unprotected termini, the compound is expected to undergo rapid proteolytic degradation by aminopeptidases and carboxypeptidases in plasma and gastrointestinal fluid; however, molecular modeling studies have demonstrated that ultrashort peptides including EDP are substrates of the proton-coupled oligopeptide transporter (POT) family carriers PEPT1 and PEPT2, supporting intestinal absorption and cellular uptake through active transport mechanisms [17, 18]. The compound is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. It is not registered as a pharmaceutical product outside the Russian Federation. Crystagen is commercially available in Russia as a dietary supplement in capsule and sublingual formulations and is supplied internationally as a research-grade lyophilized peptide by multiple peptide synthesis vendors at greater than 95 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, synthesis, and structural characterization of Crystagen; the discovery and development history within the Khavinson bioregulatory peptide program; the molecular pharmacology including peptide-DNA binding, histone interaction, and gene expression modulation; the pharmacokinetic considerations for ultrashort peptides; the preclinical pharmacology across immune, inflammatory, and aging cell models; the clinical evidence base (observational); sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five immunomodulatory peptide candidates (Thymogen, Vilon, Thymosin alpha-1, Thymulin, Epithalon) against Crystagen on five competency standards.